Screening for Multidrug Resistance in Leukemia: Cell Reactivity to MRK-16 Correlates with Anthracycline Retention and Sensitivity of Leukemic Cells

References

• Beck W. T. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II and other factors. Cancer Treat. Res. 1990; 17(suppl. A)11–20
   Google Scholar
• Kaye S. B. The multidrug resistance phenotype. Br. J. Cancer 1988; 58: 691–694
   PubMed Web of Science ®Google Scholar
• Weinstein R. S., Kuszak J. R., Kluskens L. F., Coon J. S. P-glycoprotein in pathology: the multidrug resistance gene family in humans. Human Pathol. 1990; 21: 34–48
   PubMed Web of Science ®Google Scholar
• Nooter K., Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer 1991; 63: 663–669
   PubMed Web of Science ®Google Scholar
• Choi K., Frommel T. O., Kaplan Stem R., et al. Multidrug resistance after retroviral transfer of the human MDR 1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc. Natl. Acad. Sci. USA 1991; 88: 7486–7390
   PubMed Web of Science ®Google Scholar
• Lincke C. R., Van Der Bliek A. M., Schuurhuis G. J., et al. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 1989; 1779–1785
   Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Dossot J. M., Fardel O., et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2398
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemia: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Geromin A., et al. Overexpression of multidrug resistance-associated p 170-glycoprotein in acute non-lymphocytic leukemia. Eur. J. Haematol. 1992; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Michieli M., Giacca M., Fanin R., et al. mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment. Br. J. Haematol. 1991; 78: 290–291
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., et al. Expression of multidrug resistance gene (mdr-1) in human normal leukocytes. Haematologica 1993; 78: 12–17
   PubMedGoogle Scholar
• Drach D., Zhao S., Drach J., et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Pileri S., Sabattini E., Falini B., et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19: 131–140
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Roninson I. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., et al. P170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 1994; 79: 119–126
   PubMed Web of Science ®Google Scholar
• Russo D., Marie J. P., Zhou D. C., et al. Evaluation of the clinical relevance of the anionic glutathione-s-transferase (GSTTκ) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas. Leukemia & Lymphoma 1994; 15: 453–468
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., et al. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukemia. Leukemia & Lymphoma 1995; 17: 289–294
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., et al. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79: 500–507
   PubMed Web of Science ®Google Scholar
• Luk C. K., Tannock I. H. Flow cytometry analysis of doxorubicin accumulation in cells from human and rodent cell lines. J. Natl. Cancer Inst. 1989; 81: 55–63
   PubMed Web of Science ®Google Scholar
• Pieters R., Huismans D. R., Leyva A., et al. Comparison of a rapid automated tetrazolium based (MTT)-assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br. J. Cancer 1989; 59: 217–220
   PubMed Web of Science ®Google Scholar
• List A. F., Spier C. M., Cline A., et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Brit. J. Haematol. 1991; 78: 28–34
   PubMed Web of Science ®Google Scholar
• Sonnenveld P., Van Dongen J. J. M., Hagemeijer A., et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993; 7: 963–969
   PubMed Web of Science ®Google Scholar
• Lamy T., Goasguen J. E., Mordelet E., et al. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994; 8: 1879–1883
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Dossot J. M., Fardel O., et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2398
   PubMed Web of Science ®Google Scholar
• Van Acker K. L., Van Hove L. M., Boogaerts M. A. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies. Cytometry 1993; 14: 736–746
   PubMedGoogle Scholar
• Krishan A., Sauerteig A. N., Stein J. H., et al. Comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry 1991; 12: 731–742
   PubMedGoogle Scholar
• Lehne G., De Angelis P., Clausen O. P. F., et al. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry 1995; 20: 228–237
   PubMedGoogle Scholar
• Cumber P. M., Jacobs A., Hoy T., et al. Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein. Leukemia 1991; 5: 1050–1053
   PubMed Web of Science ®Google Scholar
• Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Campos L., Guyatat D., Jaffar C., et al. Correlation of MDR 1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur. J. Haematol 1992; 48: 254–258
   PubMed Web of Science ®Google Scholar
• Ross D. D., Wootern P. J., Sridhara R., et al. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288–1299
   PubMed Web of Science ®Google Scholar
• Ino T., Miyazaki H., Isogai M., et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlations with treatment outcome. Leukemia 1994; 8: 1492–1497
   PubMed Web of Science ®Google Scholar
• Bailly D., Muller C., Jaffrezou J. P., et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995; 9: 799–807
   PubMed Web of Science ®Google Scholar
• Schepper R. J., Broxterman H. J., Scheffer G. L., et al. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Flens M. J., Izquerdo M. A., Scheffer G. L., et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994; 54: 4557–4563
   PubMed Web of Science ®Google Scholar
• Cole S. P. C., Sparks K. E., Fraser K., et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994; 54: 5902–5910
   PubMed Web of Science ®Google Scholar
• Zhou D. C., Zittoun R., Marie J. P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR 1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661–1666
   PubMed Web of Science ®Google Scholar
• Nair S., Singh S. V., Samy T. S. A., Krishan A. Anthracycline resistance in murine leukemic P388 cells. Role of drug efflux and glutathione related enzymes. Biochemical Pharmacol. 1990; 39: 723–728
   PubMed Web of Science ®Google Scholar
• Whelan R. D. H., Hosking L. K., Townsend A. J., et al. Differential increases in glutathione-s-transferase activities in a range of multidrug-resistant tumor cell lines. Cancer Communications 1989; 1: 359–365
   PubMedGoogle Scholar
• Marie J. P., Simonin G., Legrand O., et al. Glutathione-S-transferase κ, α, μ and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 1995; 9: 1742–1747
   PubMed Web of Science ®Google Scholar
• Kaufmann S. H., Karp J. E., Jones R. J., et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517–530
   PubMed Web of Science ®Google Scholar
• Morrow C. S., Cowan K. H. Multidrug resistance associated with altered topoisomerase II activity—topoisomerases II as targets for rational drug design. J. Natl. Cancer Inst. 1990; 82: 638–639
   PubMed Web of Science ®Google Scholar